Aimmune raises $176M in bumped up follow-on

Allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised $176 million on Feb. 22 through the sale of 5.5 million shares at $32 in a bumped-up follow-on. Underwriters were BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit Suisse, RBC Capital Markets, Roth Capital Partners and Wedbush PacGrow. The price is an 8% discount to Aimmune's closing price of $34.96 on Feb. 20, when it proposed after market hours to raise $150 million...